Michael M Mckeown DeceasedBarrington, RI

7119077, Oct 10, 2006

Mar 15, 2000

09/526298

Ronald M. Evans - La Jolla CA, US
Michael B. McKeown - San Diego CA, US
Anthony E. Oro - San Diego CA, US
William A. Segraves - Ambler PA, US
Tso-Pang Yao - La Jolla CA, US

The Salk Institute for Biological Studies - La Jolla CA

C07H 21/04
A61K 48/00

514 44, 435 6, 435440, 435375

In accordance with the present invention, it has been discovered that various members of the steroid/thyroid superfamily of receptors can interact with the insect-derived ultraspiracle receptor, to form multimeric species. Accordingly, the interaction of at least one member of the steroid/thyroid superfamily of receptors with at least the dimerization domain of the ultraspiracle receptor modulates the ability of said member of the steroid/thyroid superfamily of receptors to transactivate transcription of genes maintained under hormone expression control in the presence of the cognate ligand for said member of the superfamily.

2002001, Jan 24, 2002

Feb 9, 2001

09/780258

Michael McKeown - Barrington RI, US

A01K067/00
A01K067/033
C12N009/64
A61K048/00

800/008000, 435/226000, 514/044000, 514/012000

The present invention relates generally to factors contributing to neurodegenerative behavior, and more specifically to the Kelch family of genes. It has been identified that mutant forms of Kelch lead to significant deterioration of behavior and body control while not decreasing life span, a phenotype similar to many human deterioration diseases. The present invention establishes that the Kelch family of genes is involved in maintenance of proper neural function with aging, e.g., in animals, including insects and mammal (including humans).

2016016, Jun 16, 2016

Jul 25, 2014

14/907339

- Boston MA, US
Wei Zhang - Sharon MA, US
Jun Qi - Sharon MA, US
Michael R. McKeown - Brookline MA, US
Harry Hongning Fu - Newton MA, US
Shuai Liu - Dorchester MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA
University of Massachusetts - Boston MA

C07D 487/04
C07D 491/048
C07D 471/04
C07D 413/10

The present invention provides novel compounds of any one of Formulae (I) to (IV), and pharmaceutically compositions thereof. Compounds of any one of Formulae (I) to (IV) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (BETs)). Also provided are methods, uses, and kits using the inventive compounds and pharmaceutical compositions for inhibiting the activity of the bromodomain-containing proteins and for treating and/or preventing in a subject in need thereof diseases associated with bromodomain-containing proteins, such as proliferative diseases.